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Abstract
Background: Acute severe haemorrhage is a common complication of injury, childbirth, surgery, gastrointestinal
pathologies and other medical conditions. Bleeding is a major cause of death, but patients also die from non-bleeding
causes, the frequency of which varies by the site of haemorrhage and between populations. Because patients can bleed
to death within hours, established interventions inevitably take priority over randomisation into a trial. These
circumstances raise challenges in selecting appropriate outcome measures for clinical trials of haemostatic interventions.
Main body: We use data from three large randomised controlled trials in acute severe haemorrhage (CRASH-2, WOMAN
and HALT-IT) to explore the strengths and limitations of outcome measures commonly used in trials of haemostatic
treatments, including all-cause and cause-specific mortality, blood transfusion and surgical interventions. Many deaths
following acute severe haemorrhage are due to patient comorbidities or complications rather than bleeding. If non-
bleeding deaths are unaffected by a haemostatic intervention, even large trials will have low power to detect an effect
on all-cause mortality. Due to the dilution from deaths unaffected or reduced by the trial treatment, all-cause mortality
can also obscure important harmful effects. Additionally, because the relative contributions of different causes of death
vary within and between patient populations, all-cause mortality is not generalisable. Different causes of death occur at
different time intervals from bleeding onset, with bleeding deaths generally occurring early. Time-specific mortality can
therefore be used as a proxy for cause in un-blinded trials where bias is a concern or in situations where cause of death
cannot be assessed. Urgent treatment is critical, and so post-randomisation blood transfusion and surgery are often
planned before or at the time of randomisation and therefore cannot be influenced by the trial treatment.
Conclusions: All-cause mortality has low power, lacks generalisability and can obscure harmful effects. Cause-specific
mortality, such as death due to bleeding or thrombosis, avoids these drawbacks. In certain scenarios, time-specific
mortality can be used as a proxy for cause-specific mortality. Blood transfusion and surgical procedures have limited
utility as outcome measures in trials of haemostatic treatments.
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Background
Acute severe haemorrhage is a common complication of
injury, childbirth, surgery, gastrointestinal pathologies
and other medical conditions. Regardless of the cause,
serious bleeding often has similar pathophysiological
consequences, such as those mediated by hypovolemic
shock. Although efforts to achieve haemostasis depend
on the site of bleeding, treatments to support coagula-
tion and maintain vital organ perfusion are not site
specific and are often included in generic major haemor-
rhage protocols [1]. For these reasons, clinical trials
assessing the risks and benefits of haemostatic treat-
ments often evaluate the same patient outcomes regard-
less of the cause or site of bleeding [2–4].
Outcomes in clinical trials should be relevant to pa-
tients, amenable to unbiased assessment and have the
potential to be influenced by the trial treatment. Because
trial results inform the care of different patients, in dif-
ferent places and at different times, we must also con-
sider generalisability when selecting outcomes. We use
data from large randomised placebo-controlled trials of
tranexamic acid in acute severe bleeding (postpartum,
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traumatic and gastrointestinal) to assess the extent to
which commonly used outcome measures meet these
criteria. The CRASH-2 trial is a randomised trial of tran-
examic acid in 20,211 trauma patients with, or at risk of,
significant bleeding, within 8 h of injury [5]. The
WOMAN trial is a randomised trial of tranexamic acid
in 20,060 women with postpartum haemorrhage [6]. The
HALT-IT trial is a randomised trial of tranexamic acid
in 12,000 patients with significant gastrointestinal bleed-
ing [7]. The methods are described in detail elsewhere
[5–7]. The HALT-It trial is ongoing, but blinded data on
8699 patients are used in these analyses.
All-cause or cause-specific mortality?
Because death is important to patients, easy to quantify
and may be affected by treatment, it is an important out-
come measure in clinical trials in life-threatening bleeding.
All-cause mortality is unequivocal and avoids any uncer-
tainties in correctly ascribing the cause of death [8, 9].
Nevertheless, all-cause mortality has important disadvan-
tages as an outcome measure in clinical trials [8, 10, 11].
Lower power for all-cause mortality
Many deaths following acute severe haemorrhage are due
to patient comorbidities or complications rather than the
failure to control bleeding. For example, patients with
acute upper gastrointestinal bleeding secondary to gastric
cancer may survive the acute bleed but die from cancer
within the trial follow-up period. Although a haemostatic
treatment might affect deaths from bleeding or throm-
bosis, it would be unrealistic to expect similar, if any, ef-
fects on other causes of death. This can lead to low power
for all-cause mortality, even in large trials [11].
Table 1 shows the causes of death in patients with
postpartum, traumatic and gastrointestinal haemorrhage.
Although bleeding is important in each scenario, the
contribution of non-bleeding deaths to all-cause mortal-
ity varies between 30 and 65% (see Fig. 1). Since there is
usually no reason why a haemostatic intervention would
reduce non-bleeding deaths, the effect of the interven-
tion on all-cause mortality will be smaller than the effect
on death from bleeding. More precisely, the effect on
all-cause mortality will be a weighted average of the ef-
fects on specific causes of death, weighted according to
their relative contribution to all-cause mortality (see
Fig. 2). If non-bleeding deaths are common and are un-
affected by the trial treatment, the dilution will be con-
siderable, and a trial would have low power for all-cause
mortality, even if there was a significant reduction in
bleeding deaths. Sample size depends inversely on the
square of the effect size, so a bigger sample is needed to
achieve the same power for all-cause mortality as for
cause-specific mortality [12]. For example, four times as
many patients are needed if only 50% of deaths are due
to the cause being affected by the trial medication (i.e.
bleeding), and nine times as many are needed if a third
of deaths are due to the relevant cause.
Important safety signals may be obscured in all-cause
mortality
Due to the dilution from deaths unaffected or reduced
by the trial treatment, all-cause mortality can also ob-
scure important harmful effects, which are typically rarer
and also need to be considered on a cause-specific basis
[10, 11]. For example, there is strong evidence that the
effect of tranexamic acid on bleeding deaths varies by
time to treatment, with a 10% decrease in survival bene-
fit for every 15-min delay [13]. Treatment given more
than 3 h from bleeding onset is ineffective and possibly
harmful [14]. However, this strong time-to-treatment
interaction is obscured in analyses of all-cause mortality
(see Fig. 3). For the same reason, we must assess separ-
ately any potential adverse effects of haemostatic treat-
ments (e.g. increased risk of thrombotic deaths). These
are often missed in all-cause endpoints due to the effect
being swamped and obscured by other causes of death.
Risk-benefit decisions in individuals also require separate
assessment of benefits and harms because the baseline
risks vary between patients. A haemostatic drug might
reduce all-cause mortality in a young patient at low
baseline risk of thrombosis but not in an older patient
with cardiovascular comorbidity.
Generalisability
Because the relative contribution of different causes of
death varies within and between patient populations,
all-cause mortality is not generalisable. For example, in the
CRASH-2 trial, bleeding accounted for 60% of deaths in pa-
tients with penetrating trauma compared to 25% of deaths
in patients with blunt trauma. There was a substantial re-
duction in death due to bleeding with tranexamic acid, with
no heterogeneity by type of injury, but no reduction in
non-bleeding deaths (see Table 2). Consequently, although
the effect of tranexamic acid on death due to bleeding is es-
sentially the same in blunt and penetrating injury, it will
have a larger effect on all-cause mortality in populations
where penetrating trauma is common.
Misclassification of cause of death
The main concern with cause-specific mortality is that
cause of death is determined subjectively and can be mis-
classified [15, 16]. For blinded trials, any misclassification
would be unrelated to treatment allocation and so will not
introduce bias. Although misclassification of cause of death
might dilute the effect of the treatment on cause-specific
mortality, the power of a trial to detect a slightly diluted
measure of the relevant (generalisable) outcome should be
higher than that for all-cause mortality. When cause of
Brenner et al. Trials  (2018) 19:533 Page 2 of 7
death is ascertained by methods with very low sensitivity
and specificity, the power of a trial to detect a treatment ef-
fect on cause-specific and all-cause mortality may be similar
[17]. This also occurs when most of the deaths are due to
the cause under study. Although independent, blinded
event adjudication by an endpoint review committee is
thought to provide an unbiased and systematic method for
evaluating causes of death in clinical trials, there is little
empirical evidence that this has any substantial effect on
trial accuracy [18–20].
Time-specific mortality
Misclassification of cause of death is a particular con-
cern in un-blinded trials, where knowledge of group al-
location might influence decisions about cause of death
and introduce bias. Because different causes of death
occur at different time intervals from bleeding onset,
time-specific mortality can help maintain objectivity
whilst avoiding the drawbacks of all-cause mortality.
Table 1 shows the time interval between hospital admission
and death by cause of death and site of haemorrhage. Most
bleeding deaths occur within 48 h of admission, followed
by deaths from vascular occlusion and multi-organ failure,
with sepsis deaths about 1 week later. Table 2 shows the ef-
fect of tranexamic acid on death due to bleeding and death
within 48 h of admission in traumatic and postpartum
haemorrhage. The results are similar, suggesting deaths
within 48 h of admission might be used as a proxy for
bleeding deaths in non-blinded trials. Although some mis-
classification is inevitable, especially if there are many early
non-bleeding deaths, misclassification rates should not dif-
fer by allocated group.
In some scenarios, re-bleeding is common and can
cause death. More than half of patients with liver disease
who survive an episode of variceal bleeding will re-bleed
within a year, and one fifth of these patients will die [21].
Re-bleeding also occurs after spontaneous intracranial
haemorrhage. A patient enrolled in a trial of a haemostatic
Table 1 Cause of death and time from randomisation to death in postpartum, gastrointestinal and traumatic haemorrhage
Cause of death Postpartum haemorrhage Gastrointestinal haemorrhage Traumatic haemorrhageb
N = 20,021 N = 8,699 N = 20,127
n (%) Days (hours) n (%) Days (hours) n (%) Days (hours)
Bleeding 346 (1.7) 0 (5) 350 (4.0) 1 (28) 1063 (5.3) 0 (10)
Thrombosisa 21 (0.1) 0 (11) 32 (0.4) 4 (94) 81 (0.4) 4 (88)
Organ failure 43 (0.2) 2 (47) 141 (1.6) 5 (127) 486 (2.4) 3 (83)
Sepsis 23 (0.1) 5 (118) 109 (1.3) 6 (140) 44 (0.2) 9 (219)
Other 50 (0.2) 1 (13) 182 (2.1) 5 (114) 1402 (7.0) 1 (35)
All-cause 483 (2.4) 0 (7) 814 (9.4) 3 (66) 3076 (15.3) 1 (22)
Time to death is the median time from randomisation to death in days and hours
aIncludes stroke, myocardial infarction and pulmonary embolism
bTime to death estimated using date and time of randomisation and date of death
Fig. 1 Primary cause of death by site of acute severe haemorrhage. Other causes of death in traumatic haemorrhage include head injury (39.8%).
Other causes of death in gastrointestinal haemorrhage include cancer (10.3%) and liver disease (2.3%). Other causes of death in postpartum haemorrhage
include eclampsia (2.1%) and pulmonary oedema (1.5%)
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Fig. 2 Hypothetical model of the effect of a haemostatic treatment on all-cause and cause-specific mortality. The treatment reduces the risk of
death due to bleeding by 25% (relative risk (RR) = 0.75) but has no effect on non-bleeding deaths (RR = 1.00). The effect on all-cause
mortality (RR = 0.90) is a weighted average of the effect on cause-specific deaths, weighted according to the relative contributions of
each cause. Assuming the same number of patients in each trial arm, the RR can also be calculated as the ratio of events in the
treatment and placebo groups
Fig. 3 Effect of tranexamic acid on all-cause mortality and death due to bleeding in traumatic haemorrhage by time to treatment
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agent may survive the initial bleed but die from re-bleeding
during the follow-up. Depending on the duration of the
trial treatment and the half-life of the drug, it may be un-
realistic to expect a treatment given for the initial bleed to
influence re-bleeding deaths many days or weeks later, and
the inclusion of these re-bleeding deaths could dilute the ef-
fect. In this situation, cause-specific mortality within a spe-
cified interval of the index bleed may be more appropriate.
Time-specific death can also be a useful endpoint when
cause-specific mortality cannot be assessed. For example,
in patients with spontaneous and traumatic intracranial
bleeding it is difficult to determine the pathophysiological
process (e.g. haemorrhage, oedema, infarction) leading to
death [22–26]. However, because most intracranial bleed-
ing occurs within hours of symptom onset with significant
haematoma expansion being rare after 24 h, early deaths
are more likely to be affected by a haemostatic agent than
late deaths [24, 25]. The TICH-2 trial of tranexamic acid
in spontaneous intracranial bleeding found a significant
reduction in deaths within 7 days with less haematoma ex-
pansion, but no reduction in death at 90 days [27]. Whilst
this cannot be taken as evidence of efficacy, it suggests the
need for larger adequately powered trials.
Surgical intervention and blood transfusion as
outcome measures
Surgical interventions to control bleeding and receipt of
blood transfusion are common outcome measures in trials
of haemostatic treatments. At first sight, they appear to
satisfy our three criteria. Patients would prefer not to
undergo surgery or receive allogenic blood; these out-
comes are well documented; and both could be reduced
by an effective haemostatic treatment. However, whilst
surgery and transfusion may be suitable in bleeding pre-
vention trials, they are less appropriate in treatment trials,
where urgent treatment is critical and trial recruitment
can often take second place. The activation of major
haemorrhage protocols and decisions regarding estab-
lished interventions are likely to happen before or around
the same time as the administration of a trial treatment.
Indeed, trials in elective surgery show that tranexamic acid
reduces blood transfusion by about one third, whereas
there was no effect on transfusion in trials of tranexamic
acid for the treatment of postpartum or traumatic haem-
orrhage [5, 6, 28].
Death or hysterectomy was the primary outcome in
the WOMAN trial of tranexamic acid treatment for
postpartum haemorrhage. However, during the trial the
investigators noticed that the decision to conduct an
emergency peripartum hysterectomy was often made at
the time of randomisation. For example, in response to
life-threatening bleeding, a clinician might elect to do a
hysterectomy and then enrol the woman into the trial.
Although tranexamic acid might prevent death in these
women, it could not prevent hysterectomy. In response,
investigators increased the sample size from 15,000 to
20,000 patients to provide enough power to detect a re-
duction in bleeding deaths. On the other hand, there
was a substantial reduction in re-operation to control
bleeding with tranexamic acid. Unlike hysterectomy, the
decision to re-operate is made after randomisation and
so could be influenced by tranexamic acid.
Similarly, the receipt of blood transfusion after random-
isation is mostly determined by blood lost prior to ran-
domisation (see Additional file 1: Tables S1 and S2).
Major haemorrhage protocols triggered by estimated
blood loss or blood pressure on admission (i.e. before ran-
domisation) largely dictate the amount of blood transfused
through generic blood protocols, which specify the num-
ber and ratio of blood components transfused. Although
administered post-randomisation, transfusions given in re-
sponse to presenting clinical signs and symptoms caused
Table 2 Effect of early tranexamic acid on all-cause, cause-specific and time-specific mortality in postpartum and traumatic haemorrhage
Cause/time of death Postpartum haemorrhage Traumatic haemorrhageb All
(N = 14,923) (N = 13,484) (N = 28,407)
RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value
All-cause 0.83 (0.66–1.04) 0.099 0.87 (0.80–0.94) < 0.001 0.86 (0.80–0.93) < 0.001
Cause-specific
Haemorrhage 0.69 (0.53–0.90) 0.007 0.72 (0.63–0.83) < 0.001 0.72 (0.63–0.81) < 0.001
Thrombosisa 1.15 (0.39–3.42) 0.803 0.56 (0.31–0.99) 0.043 0.65 (0.39–1.07) 0.090
Other 1.35 (0.84–2.15) 0.213 0.99 (0.89–1.10) 0.867 1.01 (0.90–1.12) 0.908
Time-specific (hours from randomisation)
< 48 0.74 (0.58–0.95) 0.015 0.83 (0.75–0.91) < 0.001 0.81 (0.74–0.89) < 0.001
≥ 48 1.81 (0.92–3.55) 0.080 0.94 (0.81–1.10) 0.457 0.98 (0.85–1.15) 0.844
Includes patients treated within 3 h of delivery/injury only
aIncludes stroke, myocardial infarction and pulmonary embolism
bTime of death estimated using time and date of randomisation and date of death
CI confidence interval, RR relative risk
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by blood lost before randomisation cannot be affected by
the trial treatment, and this will dilute the treatment effect.
For example, if we assume 80% of post-randomisation
transfusions are given for blood lost before randomisation
(relative risk (RR) = 1.00) and 20% are given for blood lost
afterwards (RR = 0.70), the overall effect on transfusion, the
weighted average of the two, will be severely diluted
(RR = 0.94). It is also important to bear in mind that
in some countries receipt of transfusion does not
reflect blood loss due to blood shortages. Finally, if
the trial treatment improves survival, there will be a
greater opportunity to receive a transfusion in the
treatment arm. For these reasons, we should not expect a
substantial reduction in the need for transfusion in trials
of treatments for acute severe haemorrhage.
Conclusions
When a patient has acute severe bleeding, time is of
the essence, and urgent care inevitably takes priority
over the administration of a trial treatment. As such,
blood transfusion and surgery are often planned be-
fore or at the time of randomisation, and so cannot
be prevented by the trial treatment. Indeed, the only
patient outcome that can be clearly established as
following the administration of the trial treatment is
death. However, because many deaths in patients
with acute severe bleeding are from comorbidities
that may be unaffected by the trial treatment, even
large trials will have low power to detect changes in
all-cause mortality. Both benefit and harm can be
obscured in all-cause mortality, and because the rela-
tive contributions of different causes of death vary
within and between patient populations, all-cause
mortality is not generalisable. Cause-specific mortal-
ity, such as death due to bleeding or thrombosis,
avoids the drawbacks of all-cause mortality. Al-
though assigning cause involves judgement, this will
not cause bias in blind placebo-controlled trials.
Time-specific mortality can be a proxy for cause in
un-blinded trials or when cause of death cannot be
assessed. Core outcome sets for trials evaluating
treatments for life-threatening bleeding [29, 30]
should consider the results of these analyses.
Additional file
Additional file 1: Supplementary data analyses. This file provides two
tables showing the relationship between baseline characteristics and
blood transfusion in postpartum and traumatic haemorrhage.
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